Evidence mapPaperPMID 11468198Full record

Trial reportCirculation2001

Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease.

M Schartl, W Bocksch, D H Koschyk, W Voelker, K R Karsch, J Kreuzer, D Hausmann, S Beckmann, M Gross

Registry-linked trialOpen access · bronzeAbstract readClinical TrialComparative StudyMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Circulation, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01200056 (A Prospective, Double-blinded, Randomised Study to Evaluate the Effects of Different Doses of Statin Treatment on Plaque Volume and Composition in Coronary Disease Determined by Virtual Histology Using Intravascular Ultrasound), which is not on this map. Cited by 83 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 4 pooled it
20.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01200056 phase4completedstarted 2007, after this paper: background citation

A Prospective, Double-blinded, Randomised Study to Evaluate the Effects of Different Doses of Statin Treatment on Plaque Volume and Composition in Coronary Disease Determined by Virtual Histology Using Intravascular Ultrasound

Ran2007Enrolled40Registered outcomes2Posted comparisons0ConditionsCoronary Disease, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Ultrasonography, InterventionalArmsAtorvastatin 10mg versus 40mg.
Open the trial in the graph
3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 4 syntheses or guidelines pooled it, 366 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Factors Contributing to Low Utilization of Intracoronary Imaging in Clinical Practice: A White Paper.Journal of the Society for Cardiovascular Angiography & Interventions · 2025
    Review
  13. ANMCO position paper on the management of hypercholesterolaemia in patients with acute coronary syndrome.European heart journal supplements : journal of the European Society of Cardiology · 2023
    Article
  14. Article
  15. Article
  16. The role of statins in the prevention of preeclampsia.American journal of obstetrics and gynecology · 2022
    Review
  17. Article
  18. Article
  19. Review
  20. Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

M SchartlUniversitaetsklinikum Charité, Campus Virchow, German Heart Institute Berlin, Germany. michael.schartl@charite.de
W Bocksch
D H Koschyk
W Voelker
K R Karsch
J Kreuzer
D Hausmann
S Beckmann
M Gross
Heidelberg University · DERoche (United States) · USUniversity Medical Center Hamburg-Eppendorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe studied whether lipid-lowering therapy with atorvastatin (target LDL cholesterol [LDL-C] <100 mg/dL) compared with a moderate treatment regimen that used other lipid-lowering drugs led to a lesser progression of atherosclerosis and to different changes in plaque echogenicity in patients with coronary artery disease. METHODS AND

resultsThis study was a 12-month, open-label, randomized, multicenter trial, which used serial 3D intracoronary ultrasound to calculate plaque volume and plaque echogenicity. After transcatheter therapy, 131 patients were randomized (atorvastatin n=65, usual care n=66). The target plaque had to be a minor lesion (ie, a diameter stenosis of <50% on angiography). After 12 months, mean LDL-C was reduced from 155 to 86 mg/dL in the atorvastatin group and from 166 to 140 mg/dL in the usual care group. Mean absolute plaque volume showed a larger increase in the usual care group compared with the atorvastatin group (usual care 9.6+/-28.1 mm(3), atorvastatin 1.2+/-30.4 mm(3); P=0.191). The hyperechogenicity index of the plaque increased to a larger extent for the atorvastatin group than for the usual care group, with a significant treatment effect for the percent change (atorvastatin 42.2%, usual care 10.1%; P=0.021).

conclusionsOne year of lipid-lowering therapy to <100 mg/dL LDL-C most likely led to a slowdown of plaque growth of minor lesions. The significantly larger increase in plaque hyperechogenicity is most likely due to a change in plaque composition.

Indexed as

Anticholesteremic AgentsArteriosclerosisArthralgiaAtorvastatinButyratesCholesterolCholesterol, HDLCholestyramine ResinCoronary DiseaseCreatinineExanthemaHeptanoic AcidsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsPatient DropoutsPyrrolesAnticholesteremic AgentsAtorvastatinButyratesCholesterolCholesterol, HDLCholestyramine ResinCreatinineHeptanoic AcidsHydroxymethylglutaryl-CoA Reductase InhibitorsPyrrolesTriglycerides

Identifiers

PMID11468198
OpenAlexW1982982654

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.